Press Release – June 13, 2018 Princeton, NJ. The Avoca Group announced today that it has launched the Diligent® Qualification Platform, the clinical research industry’s first centralized platform for vendor qualification as well as eLuminate™, an online […]
Read More13-14 June 2018 | Dublin, Ireland
Join your peers for two insightful days of high-quality analyses and discussions focused on transforming clinical trial execution. Avoca will also unveil two new technology platforms.
Press Release – June 6, 2018 Princeton, NJ. The Avoca Group announced today that Dr. Jeff Kasher has assumed the role of Executive Chair for the Avoca Quality Consortium (AQC), its member-based industry collaborative focused on driving efficiency, improving quality, and mitigating risk in clinical trial execution. The AQC is comprised of clinical operations, quality, […]
Read MorePress Release – May 23, 2018 Princeton, NJ – The Avoca Group has announced the full speaker lineup for the 7th Annual AQC® Global Quality Summit, taking place 13-14 June 2018 in Dublin, Ireland. The theme for this year’s event – Embrace the Present. Own the Future. – focuses on today’s most innovative solutions for […]
Read MoreMay 9-10, 2018 | Philadelphia, PA
Patricia Leuchten, CEO, The Avoca Group, will participate in a panel discussion with SCRS, ACRO, ACRP, and APCR on Wednesday, May 9.
May 7-9, 2018 | Boston, MA
Dennis Salotti, VP of Operations, The Avoca Group, will participate on the panel discussion, “Balancing Oversight in the Wake of ICH E6 (R2)” in the track, Vendor Quality, Performance and Oversight.
May 3, 2018 | 1:00pm – 2:00pm EDT
In this webinar, leading practices for proactive study startup planning will be shared. Participants will learn how to effectively deliver on improved overall study quality while supporting regulatory compliance for provider oversight.
By Dennis Salotti, COO, The Avoca Group Clinical Leader – May 1, 2018 Recent revisions to the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice, as outlined in ICH E6 (R2), have provided an impetus for sponsors to reevaluate their oversight and quality management processes throughout the clinical development process. Specifically, ICH […]
Read More